[Nucleus Basalis[/entities/nucleus-basalis-meynert Of Meynert is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
The [Nucleus Basalis of Meynert[/brain-regions/nucleus-basalis-of-meynert (NBM), also known as the substantia innominata's magnocellular component, is a cluster of large cholinergic [neurons[/entities/neurons located in the basal forebrain. It is the principal source of cholinergic innervation to the entire cerebral [cortex[/brain-regions/cortex, providing approximately 70–80% of cortical acetylcholine through widespread ascending projections
[1]
. The NBM plays an essential role in attention, arousal, learning, and memory by modulating cortical excitability and synaptic plasticity through the release of [acetylcholine[/entities/acetylcholine.
The NBM is among the earliest brain structures to undergo neurodegeneration in [Alzheimer's disease[/diseases/alzheimers, with neurofibrillary tangle accumulation in the NBM preceding pathology in the [entorhinal cortex[/brain-regions/entorhinal-cortex and [hippocampus[/brain-regions/hippocampus
[2]
. Selective and severe loss of NBM [cholinergic neurons[/cell-types/cholinergic-basal-forebrain is a defining feature of AD and forms the basis of the [cholinergic hypothesis] — the rationale for the first approved AD therapies including [donepezil[/treatments/donepezil, [galantamine[/treatments/galantamine, and rivastigmine.
The NBM is situated in the substantia innominata of the basal forebrain, ventral to the globus pallidus and lateral to the [hypothalamus[/brain-regions/hypothalamus. It was first described by Theodor Meynert in 1872 and contains approximately 200,000 large (40–60 μm) [neurons[/entities/neurons in the human brain. The cholinergic [neurons[/entities/neurons are organized into distinct sectors (Ch1–Ch4 in the Mesulam classification), with Ch4 comprising the NBM proper
[3]
:
The NBM sends diffuse cholinergic projections to virtually the entire cortical mantle, with topographic organization:
| NBM Sector | Primary Cortical Target | Functional Domain |
|---|---|---|
| Anteromedial Ch4 | [prefrontal cortex[/brain-regions/prefrontal-cortex, cingulate [cortex[/brain-regions/cortex | Executive function, attention |
| Anterolateral Ch4 | Frontoparietal operculum, insular [cortex[/brain-regions/cortex | Sensory integration |
| Intermediate Ch4 | Temporal [cortex[/brain-regions/cortex, [amygdala[/brain-regions/amygdala | Memory, emotion |
| Posterior Ch4 | Superior temporal, parietal [cortex[/brain-regions/cortex | Language, spatial processing |
The NBM receives inputs from:
The NBM is the brain's principal cholinergic modulator of cortical function. Through the release of acetylcholine acting on muscarinic (M1–M5) and nicotinic receptors, the NBM regulates:
NBM [neurons[/entities/neurons express p75NTR (low-affinity neurotrophin receptor) and TrkA (high-affinity [NGF[/genes/ngf receptor). [Nerve growth factor (NGF)[/proteins/nerve-growth-factor produced by cortical target [neurons[/entities/neurons provides retrograde trophic support essential for NBM neuron survival and maintenance of the cholinergic phenotype
[5]
. Disruption of NGF signaling contributes to cholinergic neurodegeneration in AD.
The NBM undergoes severe and selective neurodegeneration in [Alzheimer's disease[/diseases/alzheimers:
[Parkinson's disease[/diseases/parkinsons and [Lewy body dementia[/diseases/lewy-body-dementia also show significant NBM cholinergic neuron loss:
The severe cholinergic deficit resulting from NBM degeneration is the direct therapeutic target of cholinesterase inhibitors, the first drugs approved for AD:
These drugs inhibit acetylcholinesterase, prolonging the action of remaining acetylcholine at synapses. While they provide symptomatic benefit, they do not prevent the ongoing loss of NBM [neurons[/entities/neurons
[4]
.
[Deep brain stimulation (DBS)[/treatments/deep-brain-stimulation of the NBM is under investigation as a potential treatment for AD and Lewy Body Dementia. Early clinical trials have shown:
Experimental approaches to deliver [NGF[/genes/ngf to the NBM (via gene therapy using AAV vectors encoding NGF, or encapsulated cell implants) aim to rescue degenerating cholinergic [neurons[/entities/neurons by restoring trophic support
[5].
MRI-based volumetry of the NBM has emerged as a biomarker for cholinergic degeneration:
This section links to atlas resources relevant to this brain region.
The study of Nucleus Basalis Of Meynert has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.